STAT+: Pharmalittle: We’re reading about rising GLP-1 use, a psychedelic therapy for depression, and moreSTAT+: Pharmalittle: We’re reading about rising GLP-1 use, a psychedelic therapy for depression, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where we have cool breezes and clear blue skies greeting us today. Who could ask for anything more? Actually, we could — it is time to reheat the coffee kettle for Read More
Outdoor air pollution linked to higher incidence of breast cancerOutdoor air pollution linked to higher incidence of breast cancer
Women living in parts of the United States with lower air quality, especially neighborhoods with heavy emissions from motor vehicles, are more likely to develop breast cancer, according to a multiyear analysis involving more than 400,000 women and 28,000 breast cancer cases.
Breastfeeding linked to lasting immune protection against breast cancerBreastfeeding linked to lasting immune protection against breast cancer
A team of researchers led by Peter Mac’s Professor Sherene Loi has uncovered how having children and breastfeeding reduces a woman’s long-term risk of breast cancer.
Tirzepatide-Hormone Therapy Combo Tied to Weight Loss in Postmenopausal WomenTirzepatide-Hormone Therapy Combo Tied to Weight Loss in Postmenopausal Women
(MedPage Today) — ORLANDO — Postmenopausal women using hormone therapy (HT) saw significantly greater weight loss while taking the dual GIP/GLP-1 receptor agonist tirzepatide than their counterparts not using HT, according to a retrospective… (MedPage Today) — ORLANDO — Postmenopausal women using hormone therapy (HT) saw significantly greater weight loss while taking the dual Read More
Weight-loss drugs like Ozempic may also curb drug and alcohol addictionWeight-loss drugs like Ozempic may also curb drug and alcohol addiction
GLP-1 drugs, originally developed for diabetes and obesity, may also curb addictive behaviors by acting on reward circuits in the brain. Early trials show reductions in alcohol intake, opioid seeking, and nicotine use. Though more research is needed, scientists believe these drugs could open a powerful new front in addiction therapy. GLP-1 drugs, originally developed Read More
Common jobs held by immigrant women may put them at increased risk of breast cancerCommon jobs held by immigrant women may put them at increased risk of breast cancer
Many immigrant women in the U.S. work in jobs that may expose them to chemicals linked to breast cancer, according to a new study led by Silent Spring Institute. The study is among the first to examine how job-related chemical exposures may contribute to breast cancer risk among foreign-born workers, especially in jobs with fewer health and safety protections.
Real-World Data Back GLP-1s in Asthma, Cardiopulmonary ConditionsReal-World Data Back GLP-1s in Asthma, Cardiopulmonary Conditions
(MedPage Today) — CHICAGO — A series of large, real-world analyses supported benefit of GLP-1 receptor agonists in cardiopulmonary indications for patients with type 2 diabetes, researchers reported at the CHEST annual meeting hosted by the… (MedPage Today) — CHICAGO — A series of large, real-world analyses supported benefit of GLP-1 receptor agonists in cardiopulmonary Read More
Bariatric surgery in a pill bottleBariatric surgery in a pill bottle
More than 37 million Americans have type 2 diabetes, a chronic disorder affecting the body’s ability to regulate and use sugar. According to the CDC, it’s the country’s seventh leading cause of death. Type 2 diabetes can be treated with lifestyle changes and medications, including insulin, a sugar-regulating hormone.
5 Mistakes I Made When I Started A GLP-15 Mistakes I Made When I Started A GLP-1
Weight loss medications can be lifesaving for people who need them — but there are errors you’ll want to avoid. Weight loss medications can be lifesaving for people who need them — but there are errors you’ll want to avoid.
Opinion: Trump’s $150-per-month GLP-1 plan won’t reach people like meOpinion: Trump’s $150-per-month GLP-1 plan won’t reach people like me
On Oct. 16, President Trump promised to slash the price of brand-name GLP-1 drugs like Ozempic and Wegovy to $150 a month. Even after a top health official suggested price negotiations between drugmakers and the administration were ongoing, the announcement sent Novo Nordisk and Eli Lilly stocks tumbling. For patients who’ve been priced out, that Read More